Gastroesophageal Junction Adenocarcinoma Clinical Trials in Ciudad Autónoma Buenos Aires

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer